219 related articles for article (PubMed ID: 8958936)
21. Leishmania susceptibility puzzle gets another twist.
Marx J
Science; 1996 Feb; 271(5251):912-3. PubMed ID: 8584928
[No Abstract] [Full Text] [Related]
22. Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major.
Yamakami K; Akao S; Tadakuma T; Nitta Y; Miyazaki J; Yoshizawa N
Immunology; 2002 Apr; 105(4):515-23. PubMed ID: 11985672
[TBL] [Abstract][Full Text] [Related]
23. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response.
Swihart K; Fruth U; Messmer N; Hug K; Behin R; Huang S; Del Giudice G; Aguet M; Louis JA
J Exp Med; 1995 Mar; 181(3):961-71. PubMed ID: 7869054
[TBL] [Abstract][Full Text] [Related]
24. The Th1/Th2 paradigm and experimental murine leishmaniasis.
Lohoff M; Gessner A; Bogdan C; Röllinghoff M
Int Arch Allergy Immunol; 1998 Mar; 115(3):191-202. PubMed ID: 9531160
[TBL] [Abstract][Full Text] [Related]
25. T helper subset differentiation in the absence of invariant chain.
Brown DR; Swier K; Moskowitz NH; Naujokas MF; Locksley RM; Reiner SL
J Exp Med; 1997 Jan; 185(1):31-41. PubMed ID: 8996239
[TBL] [Abstract][Full Text] [Related]
26. Expansion of gamma delta+ T cells in BALB/c mice infected with Leishmania major is dependent upon Th2-type CD4+ T cells.
Rosat JP; Conceiçao-Silva F; Waanders GA; Beermann F; Wilson A; Owen MJ; Hayday AC; Huang S; Aguet M; MacDonald HR
Infect Immun; 1995 Aug; 63(8):3000-4. PubMed ID: 7622222
[TBL] [Abstract][Full Text] [Related]
27. Experimental Leishmania major infection in mice: role of IL-10.
Chatelain R; Mauze S; Coffman RL
Parasite Immunol; 1999 Apr; 21(4):211-8. PubMed ID: 10320618
[TBL] [Abstract][Full Text] [Related]
28. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
[TBL] [Abstract][Full Text] [Related]
29. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice.
Hölscher C; Arendse B; Schwegmann A; Myburgh E; Brombacher F
J Immunol; 2006 Jan; 176(2):1115-21. PubMed ID: 16394000
[TBL] [Abstract][Full Text] [Related]
30. Modulation of specific T cell responses by concurrent infection with Leishmania major and LP-BM5 murine leukemia viruses.
Doherty TM; Morse HC; Coffman RL
Int Immunol; 1995 Jan; 7(1):131-8. PubMed ID: 7718509
[TBL] [Abstract][Full Text] [Related]
31. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection.
Saha B; Chattopadhyay S; Germond R; Harlan DM; Perrin PJ
Eur J Immunol; 1998 Dec; 28(12):4213-20. PubMed ID: 9862358
[TBL] [Abstract][Full Text] [Related]
32. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection.
Monteforte GM; Takeda K; Rodriguez-Sosa M; Akira S; David JR; Satoskar AR
J Immunol; 2000 Jun; 164(11):5890-3. PubMed ID: 10820270
[TBL] [Abstract][Full Text] [Related]
33. Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection.
Satoskar AR; Stamm LM; Zhang X; Satoskar AA; Okano M; Terhorst C; David JR; Wang B
J Immunol; 1999 Jun; 162(11):6747-54. PubMed ID: 10352294
[TBL] [Abstract][Full Text] [Related]
34. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.
Noormohammadi AH; Hochrein H; Curtis JM; Baldwin TM; Handman E
Vaccine; 2001 Jul; 19(28-29):4043-52. PubMed ID: 11427281
[TBL] [Abstract][Full Text] [Related]
35. An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major.
Tacchini-Cottier F; Zweifel C; Belkaid Y; Mukankundiye C; Vasei M; Launois P; Milon G; Louis JA
J Immunol; 2000 Sep; 165(5):2628-36. PubMed ID: 10946291
[TBL] [Abstract][Full Text] [Related]
36. JNK1 is required for T cell-mediated immunity against Leishmania major infection.
Constant SL; Dong C; Yang DD; Wysk M; Davis RJ; Flavell RA
J Immunol; 2000 Sep; 165(5):2671-6. PubMed ID: 10946297
[TBL] [Abstract][Full Text] [Related]
37. An in vitro model for infection with Leishmania major that mimics the immune response in mice.
Soares MB; David JR; Titus RG
Infect Immun; 1997 Jul; 65(7):2837-45. PubMed ID: 9199457
[TBL] [Abstract][Full Text] [Related]
38. Acute IL-4 Governs Pathogenic T Cell Responses during
Poudel B; Yorek MS; Mazgaeen L; Brown SA; Kanneganti TD; Gurung P
Immunohorizons; 2020 Sep; 4(9):546-560. PubMed ID: 32948646
[No Abstract] [Full Text] [Related]
39. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine.
Schwarz T; Remer KA; Nahrendorf W; Masic A; Siewe L; Müller W; Roers A; Moll H
PLoS Pathog; 2013; 9(6):e1003476. PubMed ID: 23825956
[TBL] [Abstract][Full Text] [Related]
40. Organ-specific distribution of CD4+ T1/ST2+ Th2 cells in Leishmania major infection.
Kropf P; Bickle Q; Herath S; Klemenz R; Müller I
Eur J Immunol; 2002 Sep; 32(9):2450-9. PubMed ID: 12207329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
